Kardigan Therapeutics (NASDAQ: KARD) detailed its heart-disease pipeline at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 9, 2026, emphasizing its proprietary Prolaio platform—a data science and digital health tool powered by 70 data scientists and software engineers. The platform aggregates electronic medical records, patient-reported outcomes from smartphones, and FDA-cleared wearable data, underpinning five FDA-approved algorithms and access to millions of patient-years of clinical insights. A key innovation is its use of surrogate endpoints, such as eVO2 clearance, to streamline cardiopulmonary testing for drug development.
Kardigan Therapeutics Highlights Heart-Drug Pipeline at Cantor Conference
The biotech firm outlines Phase IIb/III trials for Danicamtiv and Ataciguat, leveraging its Prolaio platform for precision cardiac therapies.
PA
Priya Anand · Equities & Earnings Desk · 18 Sept 2026 · 12:16 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
